Appili To Work on Anti-Bioterror Vaccine

Appili Therapeutics has struck an agreement to work on a vaccine that could protect people against a potential bioterror threat.
The Halifax drug discovery company said Monday it signed a licence agreement with the National Research Council of Canada to help develop ATI-1701, to vaccinate against tularemia. The vaccine will protect against bacteria called Francisella tularensis, which can cause